Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.
Orlance has raised $300K in total funding. The most recent round was Grant. The last funding was announced in July 2024.
Orlance's investors include National Institutes of Health.
Orlance is headquartered in Barcelona, Spain.
Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.
Orlance is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Orlance — Funding & Investors." VCBacked, July 10, 2024, https://www.vcbacked.co/company/orlance. Accessed July 19, 2026.
VCBacked. (2024). Orlance — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/orlance
{{cite web |title=Orlance — Funding & Investors |url=https://www.vcbacked.co/company/orlance |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated